Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.

Completed · Phase 3

Conditions studied: Acute Heart Failure

In brief

The primary objective of the study is to compare the efficacy of levosimendan and dobutamine on all-cause mortality in the 180 days following randomization.

Key facts

Study ID

NCT00348504

Run by

Abbott

People needed

1300

Starts

2003-03-01

Expected to finish

2005-06-01

Last updated by the study team

2007-11-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written, signed and dated informed consent
• Male and female patients over 18 years of age. Females of childbearing potential must have a negative pregnancy test and must refrain from breastfeeding. Women who are postmenopausal [two years since last menstrual cycle], surgically sterilised or who have undergone a hysterectomy are considered not to be of childbearing potential
• Hospitalised patients with acutely decompensated heart failure
• Left ventricular ejection fraction less than or equal to 30 % as assessed using echocardiography, radionuclide ventriculography or contrast angiography within 12 months
• Clinical need for intravenous inotropic support as evidenced by insufficient response to intravenous diuretics and/or vasodilators (nitroglycerin, nitroprusside) and at least one of the following at screening:
• oliguria (mean urine output < 30 ml/h for at least 6 hours) and not a result of hypovolemia
• dyspnoea at rest or mechanical ventilation for heart failure
• haemodynamic impairment in those patients with Swan-Ganz catheter inserted (PCWP ≥ 18 mmHg and/or Cardiac Index ≤ 2.2 l/min/m2)

You may not qualify if…

• Severe obstruction of ventricular outflow tracts such as haemodynamically significant uncorrected primary valve disease or hypertrophic cardiomyopathy or impaired ventricular filling such as restrictive cardiomyopathy
• Weight ≥ 160 kg
• Cardiac surgery within 30 days before screening
• Stroke within 3 months before screening
• Systolic blood pressure persistently less than 85 mmHg at screening or at baseline
• Heart rate persistently 130 bpm or greater at screening or at baseline
• Serum potassium less than 3.5 mmol/l at screening
• Administration of any inotropic agent (e.g. dobutamine, milrinone, amrinone, enoximone, epinephrine, norepinephrine) except digitalis or dopamine (with dose of less than or equal than 2 mg/kg/min) during the current hospitalisation
• Hypersensitivity to levosimendan or dobutamine or any of their excipients
• A history of Torsades de Pointes
• Severe renal insufficiency (serum creatinine > 450 mmol/l [5.0 mg/dl]) or on dialysis
• Significant hepatic impairment at discretion of the investigator
• Acute bleeding
• Severe anemia (haemoglobin < 8 g/dl) at screening
• Septicaemia or septic shock
• Other serious diseases limiting life expectancy considerably (e.g. end-stage cancer)
• Participation in a clinical trial with any experimental treatment within 30 days prior to screening or previous participation in the present study
• Administration of levosimendan within 30 days prior to screening

Where it is running

• Global Medical Information - Abbott — Abbott Park, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.